SDF‑1/CXCR4 induces epithelial‑mesenchymal transition through activation of the Wnt/β‑catenin signaling pathway in rat chronic allograft nephropathy

Tang,Hao; Xu,Yue; Zhang,Zijian; Zeng,Song; Dong,Wenbo; Jiao,Wenjiao; Hu,Xiaopeng

doi:10.3892/mmr.2019.10045

SDF‑1/CXCR4 induces epithelial‑mesenchymal transition through activation of the Wnt/β‑catenin signaling pathway in rat chronic allograft nephropathy

Authors:
- Hao Tang
- Yue Xu
- Zijian Zhang
- Song Zeng
- Wenbo Dong
- Wenjiao Jiao
- Xiaopeng Hu
View Affiliations

Affiliations: Urology Institute of Capital Medical University, Department of Urology, Capital Medical University Beijing Chaoyang Hospital, Beijing 100020, P.R. China
Published online on: March 15, 2019 https://doi.org/10.3892/mmr.2019.10045
Pages: 3696-3706
Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epithelial‑mesenchymal transition (EMT) has been demonstrated to serve a crucial role in the progression of interstitial fibrosis, which is one of the principal pathological features of chronic allograft nephropathy (CAN). However, to the best of our knowledge, the mechanisms of EMT in CAN have not been investigated. In the present study, the effect of stromal cell‑derived factor 1 (SDF‑1) and the Wnt signaling pathway on the progression of EMT following kidney transplantation was investigated. The CAN model was established using Fisher 344 and Lewis rats, treated with low‑dose cyclosporine with or without AMD3100. CAN was confirmed by the pathological alterations and chronic allograft damage index scoring, and EMT was confirmed by western blotting and reverse transcription‑quantitative polymerase chain reaction. In the AMD3100 group, there were lower expression levels of α‑SMA and higher expression levels of E‑cadherin, which indicated that CAN and EMT were ameliorated by AMD3100. The kidney tissue was analyzed using an mRNA + long noncoding (lnc)RNA microarray. A total of 506 mRNAs and 404 lncRNAs were demonstrated to be significantly differentially expressed between the two groups, which revealed the involvement of SDF‑1/CXC chemokine receptor 4 (CXCR4) and the Wnt pathway. SDF‑1 was demonstrated to induce EMT in vitro through the upregulation of α‑SMA, downregulation of E‑cadherin and the wound healing assay, and in the rat renal tubular epithelial cells via the nuclear accumulation of β‑catenin, which were all inhibited by either AMD3100 or DKK‑1. CXXC finger protein 5 (CXXC5), a negative regulator of the Wnt pathway, was downregulated following treatment with SDF‑1, which was inhibited by AMD3100 but not by DKK‑1. Thus, CXXC5 may be a regulator downstream of SDF‑1/CXCR4 in EMT. In conclusion, SDF‑1/CXCR4 induces EMT of renal tubular epithelial cells with the involvement of the Wnt pathway, which may be a novel mechanism and therapeutic target in kidney allograft fibrosis of rats.

View Figures

View References

1	Lamb KE, Lodhi S and Meier-Kriesche HU: Long-term renal allograft survival in the United States: A critical reappraisal. Am J Transplant. 11:450–462. 2011. View Article : Google Scholar : PubMed/NCBI
2	Gatault P, Bertrand D, Büchler M, Colosio C, Hurault de Ligny B, Weestel PF, Rerolle JP, Thierry A, Sayegh J, Moulin B, et al: Eight-year results of the Spiesser study, a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation. Transpl Int. 29:41–50. 2016. View Article : Google Scholar : PubMed/NCBI
3	Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, et al: Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’). Am J Transplant. 7:518–526. 2007. View Article : Google Scholar : PubMed/NCBI
4	Hara S: Banff 2013 update: Pearls and pitfalls in transplant renal pathology. Nephrology (Carlton). 20 (Suppl):S2–S8. 2015. View Article : Google Scholar
5	Mannon RB: Therapeutic targets in the treatment of allograft fibrosis. Am J Transplant. 6:867–875. 2006. View Article : Google Scholar : PubMed/NCBI
6	Takabatake Y, Sugiyama T, Koharah, Matsusaka T, Kurihara H, Koni PA, Nagasawa Y, Hamano T, Matsui I, Kawada N, et al: The CXCL12 (SDF-1)/CXCR4 axis is essential for the development of renal vasculature. J Am Soc Nephrol. 20:1714–1723. 2009. View Article : Google Scholar : PubMed/NCBI
7	Ge G, Zhang H, Li R and Liu H: The function of SDF-1-CXCR4 axis in SP cells-mediated protective role for renal ischemia/reperfusion injury by SHH/GLI1-ABCG2 pathway. Shock. 47:251–259. 2017. View Article : Google Scholar : PubMed/NCBI
8	Xu Y, Zhang Q, Xue W, Zeng S, Zhang Z, Zhang X and Hu X: CXC chemokine receptor 4 (CXCR4) antagonist, a novel pathway to prevent chronic allograft nephropathy. Ann Transplant. 21:728–734. 2016. View Article : Google Scholar : PubMed/NCBI
9	Hu X, Okabayashi T, Cameron AM, Wang Y, Hisada M, Li J, Raccusen LC, Zheng Q, Montgomery RA, Williams GM and Sun Z: Chimeric allografts induced by short-term treatment with stem cell-mobilizing agents result in long-term kidney transplant survival without immunosuppression: A study in rats. Am J Transplant. 16:2055–2065. 2016. View Article : Google Scholar : PubMed/NCBI
10	Cameron AM, Wesson RN, Ahmadi AR, Singer AL, Hu X, Okabayashi T, Wang Y, Shigoka M, Fu Y, Gao W, et al: Chimeric allografts induced by short-term treatment with stem cell mobilizing agents result in long-term kidney transplant survival without immunosuppression: II, study in miniature swine. Am J Transplant. 16:2066–2076. 2016. View Article : Google Scholar : PubMed/NCBI
11	Zou XF, Gu JH, Cui ZL, Lu YW and Gu C: CXC chemokine receptor type 4 antagonism ameliorated allograft fibrosis in rat kidney transplant model. Exp Clin Transplant. 15:448–452. 2017.PubMed/NCBI
12	Aversa I, Zolea F, Ieranò C, Bulotta S, Trotta AM, Faniello MC, De Marco C, Malanga D, Biamonte F, Viglietto G, et al: Epithelial-to-mesenchymal transition in FHC-silenced cells: The role of CXCR4/CXCL12 axis. J Exp Clin Cancer Res. 36:1042017. View Article : Google Scholar : PubMed/NCBI
13	He G, Ma M, Yang W, Wang H, Zhang Y and Gao MQ: SDF-1 in mammary fibroblasts of bovine with mastitis induces EMT and inflammatory response of epithelial cells. Int J Biol Sci. 13:604–614. 2017. View Article : Google Scholar : PubMed/NCBI
14	Wu CH, Song JS, Chang KH, Jan JJ, Chen CT, Chou MC, Yeh KC, Wong YC, Tseng CT, Wu SH, et al: Stem cell mobilizers targeting chemokine receptor CXCR4: Renoprotective application in acute kidney injury. J Med Chem. 58:2315–2325. 2015. View Article : Google Scholar : PubMed/NCBI
15	Yuan A, Lee Y, Choi U, Moeckel G and Karihaloo A: Chemokine receptor Cxcr4 contributes to kidney fibrosis via multiple effectors. Am J Physiol Renal Physiol. 308:F459–F472. 2015. View Article : Google Scholar : PubMed/NCBI
16	von Toerne C, Schmidt C, Adams J, Kiss E, Bedke J, Porubsky S, Gretz N, Lindenmeyer MT, Cohen CD, Gröne HJ and Nelson PJ: Wnt pathway regulation in chronic renal allograft damage. Am J Transplant. 9:2223–2239. 2009. View Article : Google Scholar : PubMed/NCBI
17	Hu TH, Yao Y, Yu S, Han LL, Wang WJ, Guo H, Tian T, Ruan ZP, Kang XM, Wang J, et al: SDF-1/CXCR4 promotes epithelial-mesenchymal transition and progression of colorectal cancer by activation of the Wnt/beta-catenin signaling pathway. Cancer Lett. 354:417–426. 2014. View Article : Google Scholar : PubMed/NCBI
18	Shan S, Lv Q, Zhao Y, Liu C, Sun Y, Xi K, Xiao J and Li C: Wnt/beta-catenin pathway is required for epithelial to mesenchymal transition in CXCL12 over expressed breast cancer cells. Int J Clin Exp Pathol. 8:12357–12367. 2015.PubMed/NCBI
19	Council NR, . Guide for the care and use of laboratory animals. Eighth. The National Academies Press; Washington, DC: 2011
20	Kahu J, Kyllonen L, Raisanen-Sokolowski A and Salmela K: Donor risk score and baseline biopsy CADI value predict kidney graft outcome. Clin Transplant. 25:E276–E283. 2011. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Shi J, Li F, Luo M, Wei J and Liu X: Distinct roles of Wnt/beta-catenin signaling in the pathogenesis of chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Mediators Inflamm. 2017:35205812017. View Article : Google Scholar : PubMed/NCBI
23	Sanchez-Duffhues G, Garcia de Vinuesa A and Ten Dijke P: Endothelial-to-mesenchymal transition in cardiovascular diseases: Developmental signaling pathways gone awry. Dev Dyn. 247:492–508. 2018. View Article : Google Scholar : PubMed/NCBI
24	Lin MF, Jungreis I and Kellis M: PhyloCSF: A comparative genomics method to distinguish protein coding and non-coding regions. Bioinformatics. 27:i275–i282. 2011. View Article : Google Scholar : PubMed/NCBI
25	Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
26	Zuk A, Gershenovich M, Ivanova Y, MacFarland RT, Fricker SP and Ledbetter S: CXCR(4)antagonism as a therapeutic approach to prevent acute kidney injury. Am J Physiol Renal Physiol. 307:F783–F797. 2014. View Article : Google Scholar : PubMed/NCBI
27	Xia R, Xu G, Huang Y, Sheng X, Xu X and Lu H: Hesperidin suppresses the migration and invasion of non-small cell lung cancer cells by inhibiting the SDF-1/CXCR-4 pathway. Life Sci. 201:111–120. 2018. View Article : Google Scholar : PubMed/NCBI
28	Taoh, Yang JJ, Shi KH and Li J: Wnt signaling pathway in cardiac fibrosis: New insights and directions. Metabolism. 65:30–40. 2016. View Article : Google Scholar : PubMed/NCBI
29	Luo K, Gu X, Liu J, Zeng G, Peng L, Huang H, Jiang M, Yang P, Li M, Yang Y, et al: Inhibition of disheveled-2 resensitizes cisplatin-resistant lung cancer cells through down-regulating Wnt/beta-catenin signaling. Exp Cell Res. 347:105–113. 2016. View Article : Google Scholar : PubMed/NCBI
30	Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P and Foidart JM: Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res. 63:2658–2664. 2003.PubMed/NCBI
31	Wong SHM, Fang CM, Chuah LH, Leong CO and Ngai SC: E-cadherin: Its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol Hematol. 121:11–22. 2018. View Article : Google Scholar : PubMed/NCBI
32	Andersson T, Sodersten E, Duckworth JK, Cascante A, Fritz N, Sacchetti P, Cervenka I, Bryja V and Hermanson O: CXXC5 is a novel BMP4-regulated modulator of Wnt signaling in neural stem cells. J Biol Chem. 284:3672–3681. 2009. View Article : Google Scholar : PubMed/NCBI
33	Kim HY, Yoon JY, Yun JH, Cho KW, Lee SH, Rhee YM, Jung HS, Lim HJ, Lee H, Choi J, et al: CXXC5 is a negative-feedback regulator of the Wnt/beta-catenin pathway involved in osteoblast differentiation. Cell Death Differ. 22:912–920. 2015. View Article : Google Scholar : PubMed/NCBI
34	Lee SH, Kim MY, Kim HY, Lee YM, Kim H, Nam KA, Roh MR, Min Do S, Chung KY and Choi KY: The dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing. J Exp Med. 212:1061–1080. 2015. View Article : Google Scholar : PubMed/NCBI
35	Lee SH, Seo SH, Lee DH, Pi LQ, Lee WS and Choi KY: Targeting of CXXC5 by a competing peptide stimulates hair regrowth and wound-induced hair neogenesis. J Invest Dermatol. 137:2260–2269. 2017. View Article : Google Scholar : PubMed/NCBI
36	Ma S, Choi J, Jin X, Kim HY, Yun JH, Lee W, Choi KY and No KT: Discovery of a small-molecule inhibitor of Dvl-CXXC5 interaction by computational approaches. J Comput Aided Mol Des. 32:643–655. 2018. View Article : Google Scholar : PubMed/NCBI